CT引导下经皮冷冻消融治疗胃癌肝转移研究初探  

Preliminary study on CT-guided percutaneous cryoablation in the treatment of liver metastasis from gastric cancer

作　　者：陈小春[1] 杨茂江[2] 王昌平[1] Chen Xiaochun;Yang Maojiang;Wang Changping(The First People's Hospital of Yibin,Yibin 644000)

机构地区：[1]四川省宜宾市第一人民医院,644000 [2]川北医学院附属医院

出　　处：《中国现代医药杂志》2020年第7期18-22,共5页Modern Medicine Journal of China

摘　　要：目的评估CT引导下经皮冷冻消融治疗胃癌肝转移(GCLM)的临床疗效与安全性。方法回顾性分析19例胃癌(伴27个肝转移灶)患者临床资料,患者均经原发性胃癌胃切除术后行冷冻消融治疗。评估总生存期(OS)、局部肿瘤无进展生存期(PFS)、复发率、生活质量以及手术并发症。结果冷冻消融治疗后,19例患者OS为5~51个月,中位OS为16.0个月,1年、2年和3年生存率分别为78.9%、43.4%、21.7%。局部肿瘤PFS为4~24个月,中位PFS为8.0个月,6个月和12个月无进展生存率分别为59.2%和23.2%。冷冻消融治疗后患者生活质量得到改善(P<0.05),未发现因技术引起的严重并发症。结论冷冻消融术可提供良好的局部控制,改善患者生活质量,并发症发生率低,可能是GCLM的有效姑息治疗方法。Objective To evaluate the clinical efficacy and safety of CT-guided percutaneous cryoablation for liver metastasis from gastric cancer(GCLM).Methods The clinical data of 19 patients with gastric cancer(with 27 liver metastasis)were retrospectively studied.The overall survival(OS),local progression free survival(PFS),recurrence rate,quality of life and surgical complications were evaluated.Results The OS was 5~51 months,and the median OS was 16.0 months.The 1-year,2-year and 3-year survival rate was 78.9%,43.4%and 21.7%,respectively.PFS ranged from 4 to 24 months,with median PFS of 8.0 months.The progression free survival rate at 6 and 12 months was 59.2%and 23.2%,respectively.After cryoablation,the quality of life of patients was improved(P<0.05),and no serious complications because of technique were found.Conclusion Cryoablation can provide good local control,improve the quality of life of patients with low incidence of complications,which may be an effectively palliative treatment for GCLM.

关 键 词：胃癌肝转移 冷冻消融 

分 类 号：R735.2[医药卫生—肿瘤] R730.44[医药卫生—临床医学]